Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura

Cock, E De; Miravitlles, Marc; González-Juanàtey, José Ramón; Perea, José Ramón Azanza

doi:10.1007/bf03320930

Cited by 50 publications

(35 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With €30,000/QALY [37] or €30,000/QALY-€45,000/QALY [38] being the threshold for determining whether a health technology is cost-effective, we have determined that MRF service for older adults with polypharmacy in community pharmacies is costeffective compared with usual dispensing. We estimated that MRF service was a dominant intervention (less costly and more effective than usual dispensing) and the acceptability curve showed that there was little uncertainty, due to the fact that 100% of the bootstrap simulations were below €30,000/QALY and €45,000/QALY.…”

Section: Discussionmentioning

confidence: 99%

Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program

et al. 2015

View full text Add to dashboard Cite

BackgroundThe concept of Pharmaceutical Care is operationalized through pharmaceutical professional services, which are patient-oriented to optimize their pharmacotherapy and to improve clinical outcomes. ObjectiveThe objective of this study was to estimate the incremental cost-effectiveness ratio (ICER) of a medication review with follow-up (MRF) service for older adults with polypharmacy in Spanish community pharmacies, against the alternative of having their medication dispensed normally. MethodsThe study was designed as a cluster randomized controlled trial, and was carried out over a time horizon of six months. The target population was older adults with polypharmacy, defined as individuals taking five or more medicines per day. The study was conducted in 178 community pharmacies in Spain. Costutility analysis adopted a health service perspective. Costs were in euros at 2014 prices and the effectiveness of the intervention was estimated as QALYs. In order to analyze the uncertainty of ICER results, we performed a nonparametric bootstrapping with 5,000 replications. ConclusionMRF service is an effective intervention for optimizing prescribed medication and improving the quality of life in older adults with polypharmacy in community pharmacies. The results from the cost-utility analysis suggest that MRF service is cost effective. Key points for decision makers-Polypharmacy is a particular concern in older adult populations, and is associated with negative health outcomes.-Medication review with follow-up is a service that attempts to optimize pharmacotherapy, not just by focusing on the process of the use of medication, but also by improving clinical outcomes for older adults.-Medication review with follow-up service is an effective intervention for optimizing prescribed medication and improving the quality of life of older adults with polypharmacy in community pharmacies. Compared with usual dispensing, this service is cost effective.3

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A cost per QALY of €30,000 is the threshold commonly accepted to be affordable by society and the health-care system, although without official recognition in Spain [16]. It has been pointed out that an important disadvantage for making recommendations on thresholds for investing in health-care interventions based on literature reviews is the disparity, uncertainty, and arbitrariness of the criteria applied by authors with which to draw conclusions [36].…”

Section: Discussionmentioning

confidence: 99%

The Use of Quality-Adjusted Life-Years in the Economic Evaluation of Health Technologies in Spain: A Review of the 1990–2009 Literature

Rodrı́guez¹,

Paz

Lizán

et al. 2011

Value in Health

View full text Add to dashboard Cite

show abstract

“…Estos estudios emplearon ambas perspectivas descritas, aunque la mayoría se centraban en estimar el valor social de las ganancias en salud [25][26][27][28][29] y únicamente un trabajo 30 estimó el coste por AV en el sistema español. Otros dos estudios se basaron en una revisión de evaluaciones económicas 16,31 . La tabla 1 recoge las estimaciones del umbral CE para España contenidas en la revisión de la literatura.…”

Section: No Es País Para Umbrales ¿O Sí? El Caso De Españaunclassified

“…A pesar de disponer de estimaciones del umbral CE en España 16,[25][26][27][28][29][30][31] , ninguna de las cifras disponibles es formalmente reconocida en la toma de decisiones. El panel de expertos mostró un consenso general sobre la necesidad de fijar un umbral explícito para España.…”

Section: Líneas De Avanceunclassified

Evaluación económica busca umbral para apoyar la toma de decisiones

García-Lorenzo

Vallejo-Torres

Trujillo‐Martín

et al. 2015

Rev. Esp. Salud Publica

View full text Add to dashboard Cite

Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura

Cited by 50 publications

References 29 publications

Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program

Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program

The Use of Quality-Adjusted Life-Years in the Economic Evaluation of Health Technologies in Spain: A Review of the 1990–2009 Literature

Evaluación económica busca umbral para apoyar la toma de decisiones

Contact Info

Product

Resources

About